Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders. Beckermann, K., Bestvina, C. M., Whisenant, J. G., Borghaei, H., Owonikoko, T., Berry, L. D., Shyr, Y., Liang, C., Selvaggi, G., Wakelee, H. A., Horn, L. LIPPINCOTT WILLIAMS & WILKINS. 2020
View details for Web of Science ID 000560368307512